Translational Development Acquisition Corp. (NASDAQ:TDACU – Get Free Report) was the target of a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 1 shares, a decrease of 99.0% from the May 31st total of 96 shares. Based on an average daily trading volume, of 2,417 shares, the days-to-cover ratio is currently 0.0 days.
Translational Development Acquisition Price Performance
Shares of Translational Development Acquisition stock opened at $12.36 on Friday. Translational Development Acquisition has a 52 week low of $10.71 and a 52 week high of $17.29. The stock has a 50 day moving average price of $11.48 and a two-hundred day moving average price of $10.84.
About Translational Development Acquisition
Translational Development Acquisition Corp. is a blank check acquisition company incorporated in Delaware. The company was formed to effect a merger, stock purchase, asset acquisition, stock exchange, reorganization or similar business combination with one or more businesses, though it has not yet identified a target for its initial transaction.
In early 2021, the company completed its initial public offering and listed its units on the Nasdaq under the ticker TDACU. Each unit comprises one Class A ordinary share and one-third of a warrant to purchase additional Class A shares, with its securities also trading separately as shares and warrants.
Following its IPO, the net proceeds from the offering are held in a trust account until the closing of an initial business combination.
Featured Articles
- Five stocks we like better than Translational Development Acquisition
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
- MarketBeat Week in Review – 06/22 – 06/26
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
Receive News & Ratings for Translational Development Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translational Development Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
